Table 12Cumulative Incidence of Death up to End of Study

All-Cause DeathsPAH-Related Deaths
Study Time PointSelexipagPlaceboSelexipagPlacebo
Month 6▬▬▬▬
Month 12▬▬▬▬
Month 18▬▬▬▬
Month 24▬▬▬▬
Up to end of study▬▬▬▬

PAH = pulmonary arterial hypertension.

Source: Additional information from the manufacturer.6

From: 3, Results

Cover of Clinical Review Report: Slexipag (Uptravi)
Clinical Review Report: Slexipag (Uptravi) [Internet].
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.